Medicina
Saila
Netherlands Cancer Institute
Amsterda, HolandaNetherlands Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (80)
2024
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162
-
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1849-1863
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
Oncologist, Vol. 28, Núm. 6, pp. E406-E415
-
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197
-
Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194
-
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
Cancer Medicine, Vol. 12, Núm. 11, pp. 12071-12083
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
-
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903
-
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Cell Reports Medicine, Vol. 4, Núm. 11
2022
-
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48
-
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
European Urology, Vol. 82, Núm. 2, pp. 212-222
-
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308
-
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
JTO Clinical and Research Reports, Vol. 3, Núm. 9
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
-
Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study
British Journal of Sports Medicine, Vol. 56, Núm. 20, pp. 1157-1170